Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy

Background: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with human epidermal growth factor receptor 2-negative (HER2(−)) advanced breast cancer is unclear. Patients and Methods: We retrospectively investigated 301 patients with HER2(−) ABC who recei...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:In Vivo
Main Authors: NAKAMOTO, SHOGO, WATANABE, JUNICHIRO, OHTANI, SHOICHIRO, MORITA, SATOSHI, IKEDA, MASAHIKO
Format: Artigo
Sprog:Inglês
Udgivet: International Institute of Anticancer Research 2020
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279844/
https://ncbi.nlm.nih.gov/pubmed/32354934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11917
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker